Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.
Follow-Up Questions
Cynata Therapeutics Ltd のCEOは誰ですか？
Dr. Kilian Kelly は Cynata Therapeutics Ltd の Chief Executive Officer で、2019 から在籍しています。
CYYNF の株価パフォーマンスは？
CYYNF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Cynata Therapeutics Ltd の主な事業テーマや業界は？
Cynata Therapeutics Ltd は Biotechnology 業界、セクターは Health Care に属しています。
